Pharmacovigilance and Risk Management

Tuesday 23 – Wednesday 24 November 2010, Brussels, Belgium

Following on from the success of last year, VIBpharma’s 6th Annual Pharmacovigilance and Risk Management Conference is set to take centre stage once more in Brussels.

Over the last couple of decades, advances in biomedical science have generated more new and complex medicines to treat a broader range of diseases and conditions than ever before. The number of people taking medications has increased dramatically, and, as a result, governments, patient groups and health advocates are demanding stronger regulatory practices and procedures, to assure the safety of medicines before and after they reach the market.

Hence, as the regulatory landscape continues to evolve it is crucial that you are keeping abreast of the changes impacting the drug safety industry to ensure that your pharmacovigilance strategies are robust and geared to compliance. In addition to this effective risk management and minimisation efforts and comprehensive benefit: risk analysis of drugs must lay the foundations for a strong drug safety strategy.

This educational 2 day conference provides a unique platform for you to address the practical approaches you can take to mitigate risks and maximise patient safety. A tailored conference will give you the opportunity to share knowledge and expertise and will provide unparalleled networking opportunities with a large number of professionals in this industry sphere.

VIBpharma’s 6th Annual Pharmacovigilance and Risk Management Conference is a must attend for all professionals working the field. Don’t miss out on the opportunity to:

Gain critical insight on the latest developments in EU-PV legislation ensuring that your strategies are always geared towards compliance and ultimately patient safety
Discover approaches for integrating effective safety risk management plans and risk minimisation measures into your overall drug safety strategy
Understand how to leverage the tools available for evaluating the effectiveness of proactive risk minimisation strategies
Identify best practice for the collection and reporting of safety data through optimal adverse event reporting and signal detection
Improve inspection readiness with the preparation of robust safety documentation
Explore the opportunities that outsourcing and offshoring can provide as part of your pharmacovigilance strategy

Key speakers include:

Regulators

Dr Shelley Gandhi, Unit Manager-Signal Management Group, Vigilance & Risk Management of Medicines
Ingebjorg Buajordet, Senior Adviser, Norwegian Medicines Agency
Karen Jaffe, Director Product Strategy, Oracle

Pharma industry

Dr Sandip Chaudhuri, Director Safety and Risk Management Lead, Pfizer
Michael Forstner, Integrated Safety Risk Manager, Roche
Dr Seema Jaitly, VP Global Medical and Scientific Affairs, Stiefle Laboratories, GSK
Dr Izabella Bossowska, EU Qualified Person, Allergan
Dr James Higginson, Safety Surveillance Adviser, Novo Nordisk
Dr Yasmine Boulkroun, EU Risk Management Plans Coordinator, Cephalon
Dr Frank Schwartz, Senior Director, Safety and Compliance, Ipsen
Dr Marina Belle, Drug Safety and Pharmacovigilance Manager, Aggregate Reports, Sandoz
Peter de Veene, Deputy QPPV, Roche